nach oben

Current Treatment Options in Gastroenterology

Erschienen in:

29.03.2021 | Colon (JC Anderson, Section Editor)

Serrated Polyposis Syndrome: an Update and Review of the Literature

verfasst von: Carol Rouphael, MD, Carole Macaron, MD, Carol A. Burke, MD

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

We present an overview on enhancing the identification of patients with serrated polyps (SPs) and serrated polyposis syndrome (SPS), and provide an update on the prevalence and risk of advanced neoplasia in SPS. We finally share recommendations on the endoscopic management of SPS patients and surveillance of first-degree relatives.

Recent findings

Detection of patients with SPS can be enhanced by recognizing the clinical criteria; tracking cumulative lifetime size, number, and location of SPs; and designing automated processes to track those polyps. The clinical criteria for SPS were revised in 2019 and provide a framework to risk-stratify patients with SPs who are at a substantially high risk of colorectal cancer (CRC) and require aggressive, yet personalized colonoscopy surveillance.

Summary

SPS remains underdiagnosed. Automated systems to identify patients with SPS have been shown to increase SPS detection earlier than a clinician. New data suggest that after clearance, a surveillance interval of 1–3 years appears safe and associated with a low risk of interval CRC.

Urbanski SJ, Kossakowska AE, Marcon N, Bruce WR. Mixed hyperplastic adenomatous polyps—an underdiagnosed entity. Report of a case of adenocarcinoma arising within a mixed hyperplastic adenomatous polyp. Am J Surg Pathol. 1984;8:551–6.CrossRef

Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol. 1990;14:524–37. https://doi.org/10.1097/00000478-199006000-00003.CrossRefPubMed

Snover DC, Jass JR, Fenoglio-Preiser C, Batts KP. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol. 2005;124:380–91. https://doi.org/10.1309/V2EP-TPLJ-RB3F-GHJL.CrossRefPubMed

Snover D, Ahnen DJ, Burt RW, et al. Serrated polyps of the colon and rectum and serrated (“hyperplastic”) polyposis. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010. p. 160–5.

Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30. https://doi.org/10.1111/j.1365-2559.2006.02549.x.CrossRefPubMed

Sarvepalli S, Garber A, Rothberg MB, Mankaney G, McMichael J, Morris-Stiff G, et al. Association of Adenoma and Proximal Sessile Serrated Polyp Detection Rates With Endoscopist Characteristics. JAMA Surg. 2019;154:627–35. https://doi.org/10.1001/jamasurg.2019.0564.CrossRefPubMedPubMedCentral

Anderson JC, Butterly LF, Weiss JE, Robinson CM. Providing data for serrated polyp detection rate benchmarks: an analysis of the New Hampshire Colonoscopy Registry. Gastrointest Endosc. 2017;85:1188–94. https://doi.org/10.1016/j.gie.2017.01.020.CrossRefPubMedPubMedCentral

Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut. 2010;59:1094–100. https://doi.org/10.1136/gut.2009.185884.CrossRefPubMed

Chow E, Lipton L, Lynch E, D’Souza R, Aragona C, Hodgkin L, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology. 2006;13:30–9. https://doi.org/10.1053/j.gastro.2006.03.046.CrossRef

10.

Ferrández A, Samowitz W, DiSario JA, Burt RW. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. Am J Gastroenterol. 2004;99:2012–8. https://doi.org/10.1111/j.1572-0241.2004.30021.x.CrossRefPubMed

11.

Lage P, Cravo M, Sousa R, Chaves P, Salazar M, Fonseca R, et al. Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study. Am J Gastroenterol. 2004;99:1779–84. https://doi.org/10.1111/j.1572-0241.2004.30178.x.CrossRefPubMed

12.

Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy. 2006;38:266–70. https://doi.org/10.1055/s-2006-925026.CrossRefPubMed

13.

• Rosty C, Brosens LAA, Dekker E, Nagtegaal ID. Serrated polyposis. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. WHO classification of Tumours: Digestive System Tumours. Lyon: IARC; 2019. p. 532–4. This reference is important because it is the updated WHO classification of serrated polyposis syndrome.

14.

Rivero-Sanchez L, Lopez-Ceron M, Carballal S, Moreira L, Bessa X, Serradesanferm A, et al. Reassessment colonoscopy to diagnose serrated polyposis syndrome in a colorectal cancer screening population. Endoscopy. 2017;49:44–53. https://doi.org/10.1055/s-0042-115640.CrossRefPubMed

15.

•• IJspeert JEG, Bevan R, Senore C, Kaminski MF, Kuipers EJ, Mroz A, et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview. Gut. 2017;66:1225–32. https://doi.org/10.1136/gutjnl-2015-310784 This paper is important because it provides the prevalence and incidence of serrated polyposis syndrome in patients ascertained by primary non-invasive versus colonoscopy colorectal cancer screening cohorts. It also was the first to highlight that serrated polyposis syndrome is the most common polyposis syndrome.CrossRefPubMed

16.

van Herwaarden YJ, Verstegen MH, Dura P, Kievit W, Drenth JP, Dekker E, et al. Low prevalence of serrated polyposis syndrome in screening populations: a systematic review. Endoscopy. 2015;47:1043–9. https://doi.org/10.1055/s-0034-1392411.CrossRefPubMed

17.

van Herwaarden YJ, Pape S, Vink-Börger E, Dura P, Nagengast FM, Epping LSM, et al. Reasons why the diagnosis of serrated polyposis syndrome is missed. Eur J Gastroenterol Hepatol. 2019;31:340–4. https://doi.org/10.1097/MEG.0000000000001328.CrossRefPubMed

18.

Vemulapalli KC, Rex DK. Failure to recognize serrated polyposis syndrome in a cohort with large sessile colorectal polyps. Gastrointest Endosc. 2012;75:1206–10. https://doi.org/10.1016/j.gie.2012.01.033.CrossRefPubMed

19.

•• Parthasarathy G, Lopez R, McMichael J, Burke CA. A natural language-based tool for diagnosis of serrated polyposis syndrome. Gastrointest Endosc. 2020;92:886–90. https://doi.org/10.1016/j.gie.2020.04.077 This study is important because it documents the lack of recognition of serrated polyposis syndrome and strategies which may enhance the ability to diagnosis serrated polyposis in individuals undergoing colonoscopy.CrossRefPubMed

20.

Bleijenberg AGC, IJspeert JEG, Carballal S, Pellise M, Jung G, van Herwaarden YJ, et al. Low Incidence of Advanced Neoplasia in Serrated Polyposis Syndrome After (Sub)total Colectomy: Results of a 5-Year International Prospective Cohort Study. Am J Gastroenterol. 2019;114:1512–9. https://doi.org/10.14309/ajg.0000000000000339.CrossRefPubMed

21.

Rodríguez-Alcalde D, Carballal S, Moreira L, Hernández L, Rodríguez-Alonso L, Rodríguez-Moranta F, et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. Endoscopy. 2019;51:142–51. https://doi.org/10.1055/a-0656-5557.CrossRefPubMed

22.

Tadepalli US, Feihel D, Miller KM, Itzkowitz SH, Freedman JS, Kornacki S, et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest Endosc. 2011;74:1360–8. https://doi.org/10.1016/j.gie.2011.08.008.CrossRefPubMed

23.

Bleijenberg AGC, van Leerdam ME, Bargeman M, Koornstra JJ, van Herwaarden YJ, Spaander MC, et al. Substantial and sustained improvement of serrated polyp detection after a simple educational intervention: results from a prospective controlled trial. Gut. 2020;69:2150–8. https://doi.org/10.1136/gutjnl-2019-319804.CrossRefPubMedPubMedCentral

24.

IJspeert JE, Bastiaansen BA, van Leerdam ME, Meijer GA, van Eeden S, Sanduleanu S, et al. Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps. Gut. 2016;65:963–70. https://doi.org/10.1136/gutjnl-2014-308411.CrossRefPubMed

25.

Pohl J, Schneider A, Vogell H, Mayer G, Kaiser G, Ell C. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. Gut. 2011;60:485–90. https://doi.org/10.1136/gut.2010.229534.CrossRefPubMed

26.

Walker RG, Landmann JK, Hewett DG, Worthley DL, Buttenshaw RL, Knight N, et al. Hyperplastic polyposis syndrome is associated with cigarette smoking, which may be a modifiable risk factor. Am J Gastroenterol. 2010;105:1642–7. https://doi.org/10.1038/ajg.2009.757.CrossRefPubMed

27.

Jasperson KW, Kanth P, Kirchhoff AC, Huismann D, Gammon A, Kohlmann W, et al. Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. Dis Colon Rectum. 2013;56:1211–6. https://doi.org/10.1097/DCR.0b013e3182a11cca.CrossRefPubMed

28.

IJspeert JE, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut. 2017;66:278–84. https://doi.org/10.1136/gutjnl-2015-310630.CrossRefPubMed

29.

Rigter LS, Spaander MCW, Aleman BMP, Bisseling TM, Moons LM, Cats A, et al. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer. 2019;125:990–9. https://doi.org/10.1002/cncr.31903.CrossRefPubMed

30.

Biller LH, Ukaegbu C, Dhingra TG, Burke CA, Chertock Y, Chittenden A, et al. Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Cancer Prev Res (Phila). 2020;13:291–8. https://doi.org/10.1158/1940-6207.CAPR-19-0416.CrossRef

31.

Gala MK, Mizukami Y, Le LP, Moriichi K, Austin T, Yamamoto M, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146:520–9. https://doi.org/10.1053/j.gastro.2013.10.045.CrossRefPubMedPubMedCentral

32.

Taupin D, Lam W, Rangiah D, McCallum L, Whittle B, Zhang Y, et al. A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred. Hum Genome Var. 2015;2:15013. https://doi.org/10.1038/hgv.2015.13.CrossRefPubMedPubMedCentral

33.

Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2017;66:1645–56. https://doi.org/10.1136/gutjnl-2016-311849.CrossRefPubMed

34.

Cauley CE, Hassab TH, Feinberg A, Church J. Sessile Serrated Polyposis: Not an Inherited Syndrome? Dis Colon Rectum. 2020;63:183–9. https://doi.org/10.1097/DCR.0000000000001537.CrossRefPubMed

35.

Quintana I, Mejías-Luque R, Terradas M, Navarro M, Piñol V, Mur P, et al. Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis. Gut. 2018;67:2230–2. https://doi.org/10.1136/gutjnl-2017-315733.CrossRefPubMed

36.

Carballal S, Rodríguez-Alcalde D, Moreira L, Hernández L, Rodríguez L, Rodríguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2016;65:1829–37. https://doi.org/10.1136/gutjnl-2015-309647.CrossRefPubMed

37.

Bleijenberg AGC, IJspeert JEG, Hazewinkel Y, Boparai KS, Oppeneer SC, Bastiaansen BAJ, et al. The long-term outcomes and natural disease course of serrated polyposis syndrome: over 10 years of prospective follow-up in a specialized center. Gastrointest Endosc. 2020;92:1098–1107.e1. https://doi.org/10.1016/j.gie.2020.04.068.CrossRefPubMed

38.

Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the risk of colorectal cancer. Dis Colon Rectum. 2004;47:2101–4. https://doi.org/10.1007/s10350-004-0709-6.CrossRefPubMed

39.

• Egoavil C, Juárez M, Guarinos C, Rodríguez-Soler M, Hernández-Illán E, Alenda C, et al. Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology. 2017;153:106–112.e2. https://doi.org/10.1053/j.gastro.2017.04.003 This is an important study because it shows that individuals with numerous serrated polyps but not meeting the WHO criteria and their first-degree relatives are at a similar prevalence and incidence of colorectal cancer as patients with serrated polyposis syndrome and their first-degree relatives.CrossRefPubMed

40.

Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et al. Recommendations for follow-up after colonoscopy and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020;158:1131–53. https://doi.org/10.1053/j.gastro.2019.10.026.CrossRefPubMedPubMedCentral

41.

National Comprehensive Cancer Network. Genetic/familial high risk assessment-colorectal. Version 1 2020 – July 21, 2020. Available at: NCCN.org. Accessed November 28, 2020

42.

Edelstein DL, Cruz-Correa M, Soto-Salgado M, Axilbund JE, Hylind LM, Romans K, et al. Risk of Colorectal and Other Cancers in Patients With Serrated Polyposis. Clin Gastroenterol Hepatol. 2015;13:1697–9. https://doi.org/10.1016/j.cgh.2015.02.003.CrossRefPubMedPubMedCentral

43.

Kalady MF, Jarrar A, Leach B, LaGuardia L, O’Malley M, Eng C, et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum. 2011;54:164–70. https://doi.org/10.1007/DCR.0b013e3181fd4c15.CrossRefPubMed

44.

Hazewinkel Y, Reitsma JB, Nagengast FM, Vasen HF, van Os TA, van Leerdam ME, et al. Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives. Familial Cancer. 2013;12:669–73. https://doi.org/10.1007/s10689-013-9643-x.CrossRefPubMed

45.

Mankaney G, Rouphael C, Burke CA. Serrated Polyposis Syndrome. Clin Gastroenterol Hepatol. 2020;18:777–9. https://doi.org/10.1016/j.cgh.2019.09.006.CrossRefPubMed

46.

van Leerdam ME, Roos VH, van Hooft JE, Dekker E, Jover R, Kaminski MF, et al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2019;51:877–95. https://doi.org/10.1055/a-0965-0605.CrossRefPubMed

47.

Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–63. https://doi.org/10.1038/ajg.2014.435.CrossRefPubMedPubMedCentral

48.

Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, East JE, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69:411–44. https://doi.org/10.1136/gutjnl-2019-31991.CrossRefPubMed

49.

MacPhail ME, Thygesen SB, Patel N, Broadley HM, Rex DK. Endoscopic control of polyp burden and expansion of surveillance intervals in serrated polyposis syndrome. Gastrointest Endosc. 2019;90:96–100. https://doi.org/10.1016/j.gie.2018.11.016.CrossRefPubMed

50.

Hassan C, Repici A, Rex DK. Serrated polyposis syndrome: risk stratification or reduction? Gut. 2016;65:1070–2. https://doi.org/10.1136/gutjnl-2015-311357.CrossRefPubMed

51.

•• Bleijenberg AG, IJspeert JE, van Herwaarden YJ, Carballal S, Pellisé M, Jung G, et al. Personalized surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut. 2020;69:112–21. https://doi.org/10.1136/gutjnl-2018-318134 This study is important because it provides observational data that specific features of colorectal polyps can safely stratify the risk of metachronous advanced neoplasia and allow surveillance to be tailored to a shorter (1 year) interval in serrated polyposis syndrome patients with high risk features and at 2-year interval for patients without those high risk features.CrossRefPubMed

52.

Boparai KS, Reitsma JB, Lemmens V, van Os TA, Mathus-Vliegen EM, Koornstra JJ, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut. 2010;59:1222–5. https://doi.org/10.1136/gut.2009.200741.CrossRefPubMed

Titel: Serrated Polyposis Syndrome: an Update and Review of the Literature
verfasst von: Carol Rouphael, MD
Carole Macaron, MD
Carol A. Burke, MD
Publikationsdatum: 29.03.2021
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology / Ausgabe 2/2021
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-021-00336-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Clinical Management of Oligopolyposis of Unknown Etiology

Management of Familial Adenomatous Polyposis

Occult Small Bowel Bleeding

Metabolomics in Advanced Liver Disease

Treatment of Micronutrient Deficiencies Pre and Post Bariatric Surgery